Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 11;10(7):232.
doi: 10.3390/cancers10070232.

Bridging Strategies to Allogeneic Transplant for Older AML Patients

Judith Hecker  1 , Isabella Miller  2 , Katharina S Götze  3 , Mareike Verbeek  4
Affiliations
Review

Bridging Strategies to Allogeneic Transplant for Older AML Patients

Judith Hecker et al. Cancers (Basel). .

Abstract

Treatment options for older patients with intermediate or high-risk acute myeloid leukemia (AML) remain unsatisfactory. Allogeneic stem cell transplantation, the treatment of choice for the majority of younger AML patients, has been hampered in elderly patients by higher treatment related mortality, comorbidities and lack of a suitable donor. With the higher availability of suitable donors as well as of reduced intensity conditioning regimens, novel low intensity treatments prior to transplantation and optimized supportive care, the number of older AML patients being successfully transplanted is steadily increasing. Against this background, we review current treatment strategies for older AML patients planned for allogeneic stem cell transplantation based on clinical trial data, discussing differences between approaches with advantages and pitfalls of each. We summarize pre-treatment considerations that need to be taken into account in this highly heterogeneous older population. Finally, we offer an outlook on areas of ongoing clinical research, including novel immunotherapeutic approaches that may improve access to curative therapies for a larger number of older AML patients.

Keywords: allogeneic stem cell transplant; bridging strategies; chemotherapy; elderly AML; hypomethylating agents.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Juliusson G., Antunovic P., Derolf Å., Lehmann S., Möllgård L., Stockelberg D., Wahlin A., Höglund M. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2014;113:4179–4187. doi: 10.1182/blood-2008-07-172007. - DOI - PubMed
    1. Jaiswal S., Fontanillas P., Flannick J., Manning A., Grauman P.V., Mar B.G., Lindsley R.C., Mermel C.H., Burtt N., Chavez A., et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. N. Engl. J. Med. 2014;371:2488–2498. doi: 10.1056/NEJMoa1408617. - DOI - PMC - PubMed
    1. Xie M., Lu C., Wang J., McLellan M.D., Johnson K.J., Wendl M.C., McMichael J.F., Schmidt H.K., Yellapantula V., Miller C.A., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 2014;20:1472–1478. doi: 10.1038/nm.3733. - DOI - PMC - PubMed
    1. Genovese G., Kähler A.K., Handsaker R.E., Lindberg J., Rose S.A., Bakhoum S.F., Chambert K., Mick E., Neale B.M., Fromer M., et al. Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. N. Engl. J. Med. 2014;371:2477–2487. doi: 10.1056/NEJMoa1409405. - DOI - PMC - PubMed
    1. Melorose J., Perroy R., Careas S. Summary for Policymakers. In: Intergovernmental Panel on Climate Change, editor. Climate Change 2013—The Physical Science Basis. Volume 1. Cambridge University Press; Cambridge, UK: 2015. pp. 1–30.

LinkOut - more resources